Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Zevra Therapeutics (ZVRA) Amortization - Deferred Charges: 2014-2021

Historic Amortization - Deferred Charges for Zevra Therapeutics (ZVRA) over the last 6 years, with Mar 2021 value amounting to $150,000.

  • Zevra Therapeutics' Amortization - Deferred Charges fell 73.73% to $150,000 in Q1 2021 from the same period last year, while for Mar 2021 it was $1.9 million, marking a year-over-year decrease of 1.98%. This contributed to the annual value of $150,000 for FY2021, which is 93.49% down from last year.
  • Latest data reveals that Zevra Therapeutics reported Amortization - Deferred Charges of $150,000 as of Q1 2021, which was down 74.23% from $582,000 recorded in Q4 2020.
  • Zevra Therapeutics' Amortization - Deferred Charges' 5-year high stood at $675,000 during Q4 2019, with a 5-year trough of $150,000 in Q1 2021.
  • Moreover, its 3-year median value for Amortization - Deferred Charges was $571,000 (2020), whereas its average is $456,778.
  • As far as peak fluctuations go, Zevra Therapeutics' Amortization - Deferred Charges spiked by 88.20% in 2020, and later plummeted by 73.73% in 2021.
  • Over the past 4 years, Zevra Therapeutics' Amortization - Deferred Charges (Quarterly) stood at $512,000 in 2018, then surged by 31.84% to $675,000 in 2019, then dropped by 13.78% to $582,000 in 2020, then slumped by 73.73% to $150,000 in 2021.
  • Its Amortization - Deferred Charges stands at $150,000 for Q1 2021, versus $582,000 for Q4 2020 and $578,000 for Q3 2020.